Edwards Lifesciences Corp
Edwards Lifesciences Corp/ US28176E1082 /
EW
|
2024-04-18 10:10:00 PM
|
Chg.
-0.79
|
Volume |
Bid2:00:00 AM |
Ask2:00:00 AM |
Market Capitalization |
Dividend Y. |
P/E Ratio |
|
86.45USD
|
-0.91%
|
3.12 mill.
Turnover: 161.52 mill. |
85.48Bid Size: 100 |
90.69Ask Size: 100 |
51.98 bill.USD |
- |
37.42 |
Business description
Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that enable them to save and enhance lives.
Management board & Supervisory board
| CEO |
| Bernard J. Zovighian |
| Management board |
| Scott B. Ullem, Donald E. Bobo Jr., Todd J. Brinton, Daveen Chopra, Dirksen J. Lehman, Jean-Luc Lemercier, Wayne Markowitz, Christine Z. McCauley, Joseph Nuzzolese |
| Supervisory board |
| Michael A. Mussallem, Kieran T. Gallahue, Leslie S. Heisz, Martha H. Marsh, Nicholas J. Valeriani, Paul A. LaViolette, Ramona Sequeira, Steven R. Loranger, Bernard J. Zovighan |
Company data
| Name: |
Edwards Lifesciences Corp. |
| Address: |
One Edwards Way,Irvine, California 92614, USA |
| Phone: |
+1-949-250-2500 |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
www.edwards.com/ |
| Industry: |
Biotechnology |
| Sector: |
Biotechnology |
| Sub sector: |
Biotechnology |
| End of financial year: |
12-31 |
| Free Float: |
83.04% |
| IPO date: |
2000-04-03 |
Company calendar
|
CW 17 | 2024-04-25
Interim Report 1st Quarter/3 Months
|
